A Phase I/II Study to Evaluate Safety and Efficacy of P276-00 in Combination With Gemcitabine in Patients With Cancer of Pancreas
This study is an open label multicenter trial to evaluate safety and efficacy of P276-00 in
combination with Gemcitabine in subjects with locally advanced or metastatic pancreatic
cancer. Primary objective in part A is to determine maximum tolerated dose (MTD) of P276-00
in combination with Gemcitabine and in part B to evaluate efficacy of this combination in
subjects with locally advanced or metastatic pancreatic cancer. In part A, cohort of 3
subjects will be enrolled at starting dose level of P276-00 which is 100 mg/m2/ day to be
given intravenously (IV) from day 1 to day 5 every 21 days. This constitutes one cycle of
P276-00. If this dose is well tolerated then next cohort will be enrolled at higher dose
level of P276-00. P276-00 dose escalation will continue until MTD of P276-00 in combination
with Gemcitabine is determined. The subsequent dose levels of P276-00 will be 140 mg/m2/day
and 185 mg/m2/day. In part B ten subjects will be evaluated at the MTD of P276-00 in
combination with Gemcitabine to evaluate efficacy of the combination. Dose of Gemcitabine
will be same in both parts of the study which is 1000mg/m2 over 30mins every week for 7
weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. Subjects will be
treated for six cycles of P276-00 in combination with Gemcitabine or until evidence of
disease progression or unacceptable toxicity. Safety evaluations will be performed at
regular intervals by means of record of vital parameters, physical examination and
laboratory investigations for hematology and biochemistry. Efficacy assessment will be
performed by means of weekly record of pain intensity, analgesic consumption, change in
weight and performance status for evaluation of clinical benefit response and by means of CT
scans at the end of every 2 cycles for evaluation of tumor response by RECIST (Response
Evaluation Criteria in Solid Tumors)
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the maximum tolerated dose (MTD) of P276-00 administered along with Gemcitabine.
3 weeks
Yes
Amol Bapaye, MS
Principal Investigator
Deenanath Mangeshkar Hospital & Research Centre, ,Pune, India
India: Drugs Controller General of India
P276-00/28/08
NCT00898287
May 2009
Name | Location |
---|